Zargar H., Espiritu P.N., Fairey A.S., Mertens L.S., Dinney C.P., Mir M.C., Krabbe L.-M., Cookson M.S., Jacobsen N.-E., Gandhi N.M., Griffin J., Montgomery J.S., Vasdev N., Yu E.Y., Youssef D., Xylinas E., Campain N.J., Kassouf W., Dall’Era M.A., Seah J.-A., Ercole C.E., Horenblas S., Sridhar S.S., McGrath J.S., Aning J., Shariat S.F., Wright J.L., Thorpe A.C., Morgan T.M., Holzbeierlein J.M., Bivalacqua T.J., North S., Barocas D.A., Lotan Y., Garcia J.A., Stephenson A.J., Shah J.B., Van Rhijn B.W., Daneshmand S., Spiess P.E., Black P.C.
European Urology 2014 67:2 (241-249)
Background The efficacy of neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (BCa) was established primarily with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), with complete response rates (pT0) as high as 38%. However, because of the comparable efficacy with better tolerability of gemcitabine and cisplatin (GC) in patients with metastatic disease, GC has become the most commonly used regimen in the neoadjuvant setting. Objective We aimed to assess real-world pathologic response rates to NAC with different regimens in a large, multicenter cohort. Design, setting, and participants Data were collected retrospectively at 19 centers on patients with clinical cT2-4aN0M0 urothelial carcinoma of the bladder who received at least three cycles of NAC, followed by radical cystectomy (RC), between 2000 and 2013. Intervention NAC and RC. Outcome measurements and statistical analysis The primary outcome was pathologic stage at cystectomy…(vermás)